GALE 301

Drug Profile

GALE 301

Alternative Names: E39 peptide vaccine; E39+GM-CSF vaccine; FBP-E39; Folate Binding Protein-E39 vaccine; GALE-301

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; University of Texas M. D. Anderson Cancer Center
  • Developer Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides; Protein-vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer
  • Phase I/II Breast cancer

Most Recent Events

  • 30 Jun 2018 Sellas Life Sciences Group has patent protection for GALE 301 in USA
  • 29 Dec 2017 Galena Biopharma merged with Sellas Life Sciences and subsequently changed its name to Sellas Life Sciences Group
  • 17 Mar 2017 Final adverse events data from a phase I/IIa trial in Ovarian and Endometrial cancer released by Galena Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top